Mustang Bio Announces First Subject Treated in Phase 1/2 Trial with the Optimized CD20-targeted CAR T Cell Therapy MB-106

Avenue Therapeutics Announces New Drug Application for IV Tramadol Accepted for Review by FDA

Fortress Biotech Announces Pricing of Series A Preferred Stock Offering